Clinical Trial Update: Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC [Phase 1, Phase 2]

View source ↗

Summary

A completed early-phase study evaluating erlotinib with or without entinostat (SNDX-275) in advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Carcinoma

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Entinostat (entinostat)

Snippet

Sponsor: Syndax Pharmaceuticals | Conditions: Non-Small-Cell Lung Carcinoma, Carcinoma, Non-Small Cell Lung | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-06-28